Neuronetics, Inc. (STIM)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 4
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3, so the strategy cannot admit a bullish entry despite the strong technical trend.
Company overview
Neuronetics, Inc. is a medical technology company focused on developing and distributing solutions for neurohealth conditions. Its main product, the NeuroStar Advanced Therapy System, offers non-surgical treatment for major depressive disorder using transcranial magnetic stimulation. The company, headquartered in Malvern, Pennsylvania, markets directly to psychiatrists.
Fundamental
very weakNeuronetics faces going-concern risk and ongoing cash burn, despite revenue growth from acquisitions.
Neuronetics’ revenue base expanded sharply with the Greenbrook acquisition, and 2026 year-to-date results show improving net losses and slightly better gross margin. However, the latest 10‑Q (quarter ended June 30, 2026) includes an explicit substantial‑doubt going‑concern statement driven by projected minimum‑revenue covenant non-compliance; cash was about $19.2M at quarter-end and operating cash flow remained negative. With negative profitability, weak solvency indicators (Altman Z‑Score in the distress zone), and ongoing dilution/financing dependence, the fundamentals remain highly speculative despite a reasonable-looking EV/Sales multiple and visible insider buying.
Sentiment
very weakMedia sentiment is mildly positive, but going-concern warnings dominate the narrative.
Media tone improved modestly after the 2026-08-11 Q2 update (last ~14d polarity_score≈+0.23 vs ~0.00 baseline), but the same reporting cycle surfaced a substantial-doubt going‑concern warning tied to debt covenants, which can dominate near-term trading. Severe red-flag cap applied.
Technical
goodThe stock is in a strong uptrend, supported by positive momentum and trend indicators.
I score the chart 4/5 because trend, momentum, and long-side structure are strong: price is above SMA20/50/200 and EMA9/21, MACD is above zero and above its signal, and ADX 53.14 confirms persistent trend strength. It is not a 5 because ATR is very high at about 9.55% of price, price is only slightly above WMA9 and below DEMA/TEMA, and follow-through volume has normalized after the 2026-08-11 earnings burst.
You’re looking at 2026-08-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.